Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.

Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, Rosenthal A, Tausche AK, Reginato A, Manger B, Sciré C, Pineda C, van Durme C, Lin CT, Yin C, Albert DA, Biernat-Kaluza E, Roddy E, Pascual E, Becce F, Perez-Ruiz F, Sivera F, Lioté F, Schett G, Nuki G, Filippou G, McCarthy G, da Rocha Castelar Pinheiro G, Ea HK, Tupinambá HA, Yamanaka H, Choi HK, Mackay J, ODell JR, Vázquez Mellado J, Singh JA, Fitzgerald JD, Jacobsson LTH, Joosten L, Harrold LR, Stamp L, Andrés M, Gutierrez M, Kuwabara M, Dehlin M, Janssen M, Doherty M, Hershfield MS, Pillinger M, Edwards NL, Schlesinger N, Kumar N, Slot O, Ottaviani S, Richette P, MacMullan PA, Chapman PT, Lipsky PE, Robinson P, Khanna PP, Gancheva RN, Grainger R, Johnson RJ, Te Kampe R, Keenan RT, Tedeschi SK, Kim S, Choi SJ, Fields TR, Bardin T, Uhlig T, Jansen T, Merriman T, Pascart T, Neogi T, Klück V, Louthrenoo W, Dalbeth N.

Ann Rheum Dis. 2019 Nov;78(11):1592-1600. doi: 10.1136/annrheumdis-2019-215933. Epub 2019 Sep 9.

PMID:
31501138
2.

Experience of finding footwear and factors contributing to footwear choice in people with gout: a mixed methods study using a web-based survey.

Brenton-Rule A, Dalbeth N, Edwards NL, Rome K.

J Foot Ankle Res. 2019 Jan 8;12:3. doi: 10.1186/s13047-018-0313-y. eCollection 2019.

3.

Patient Perceptions of Gout Management Goals: A Cross-sectional Internet Survey.

Singh JA, Edwards NL.

J Clin Rheumatol. 2019 Jan 4. doi: 10.1097/RHU.0000000000000981. [Epub ahead of print]

PMID:
30614892
4.

Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.

Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, da Rocha Castelar-Pinheiro G, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N.

Arthritis Care Res (Hoboken). 2019 Mar;71(3):427-434. doi: 10.1002/acr.23607.

PMID:
29799677
5.

EULAR gout treatment guidelines by Richette et al.: uric acid and neurocognition.

Singh JA, Edwards NL.

Ann Rheum Dis. 2018 Apr;77(4):e20. doi: 10.1136/annrheumdis-2017-211418. Epub 2017 Mar 27. No abstract available.

PMID:
28347993
6.

Renal dosing of allopurinol results in suboptimal gout care.

Neogi T, Dalbeth N, Stamp L, Castelar G, Fitzgerald J, Gaffo A, Mikuls TR, Singh J, Vázquez-Mellado J, Edwards NL.

Ann Rheum Dis. 2017 Jan;76(1):e1. doi: 10.1136/annrheumdis-2016-210352. Epub 2016 Aug 31. No abstract available.

PMID:
27582422
7.

Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?

Ruoff G, Edwards NL.

Postgrad Med. 2016 Sep;128(7):706-15. doi: 10.1080/00325481.2016.1221732. Epub 2016 Aug 25. Review.

PMID:
27558643
8.

A cross-sectional internet-based patient survey of the management strategies for gout.

Singh JA, Shah N, Edwards NL.

BMC Complement Altern Med. 2016 Mar 1;16:90. doi: 10.1186/s12906-016-1067-3.

9.

2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ.

Ann Rheum Dis. 2015 Oct;74(10):1789-98. doi: 10.1136/annrheumdis-2015-208237. Erratum in: Ann Rheum Dis. 2016 Feb;75(2):473.

10.

2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vazquez-Mellado J, Yarows SA, Taylor WJ.

Arthritis Rheumatol. 2015 Oct;67(10):2557-68. doi: 10.1002/art.39254. Erratum in: Arthritis Rheumatol. 2016 Feb;68(2):515. Vaquez-Mellado, Janitzia [corrected to Vazquez-Mellado, Janitzia].

11.

An internet survey of common treatments used by patients with gout including cherry extract and juice and other dietary supplements.

Singh JA, Bharat A, Edwards NL.

J Clin Rheumatol. 2015 Jun;21(4):225-6. doi: 10.1097/RHU.0000000000000246. No abstract available.

12.

Emerging therapies for gout.

Edwards NL, So A.

Rheum Dis Clin North Am. 2014 May;40(2):375-87. doi: 10.1016/j.rdc.2014.01.013. Epub 2014 Feb 20. Review.

PMID:
24703353
13.

Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout.

Taylor WJ, Redden D, Dalbeth N, Schumacher HR, Edwards NL, Simon LS, John MR, Essex MN, Watson DJ, Evans R, Rome K, Singh JA.

J Rheumatol. 2014 Mar;41(3):574-80. doi: 10.3899/jrheum.131245. Epub 2014 Jan 15.

14.

OMERACT endorsement of measures of outcome for studies of acute gout.

Singh JA, Taylor WJ, Dalbeth N, Simon LS, Sundy J, Grainger R, Alten R, March L, Strand V, Wells G, Khanna D, McQueen F, Schlesinger N, Boonen A, Boers M, Saag KG, Schumacher HR, Edwards NL.

J Rheumatol. 2014 Mar;41(3):569-73. doi: 10.3899/jrheum.131246. Epub 2013 Dec 15.

15.

A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria.

Prowse RL, Dalbeth N, Kavanaugh A, Adebajo AO, Gaffo AL, Terkeltaub R, Mandell BF, Suryana BP, Goldenstein-Schainberg C, Diaz-Torne C, Khanna D, Lioté F, Mccarthy G, Kerr GS, Yamanaka H, Janssens H, Baraf HF, Chen JH, Vazquez-Mellado J, Harrold LR, Stamp LK, Van De Laar MA, Janssen M, Doherty M, Boers M, Edwards NL, Gow P, Chapman P, Khanna P, Helliwell PS, Grainger R, Schumacher HR, Neogi T, Jansen TL, Louthrenoo W, Sivera F, Taylor WJ, Alten R.

J Rheumatol. 2013 Apr;40(4):498-505. doi: 10.3899/jrheum.121037. Epub 2013 Feb 15. Erratum in: J Rheumatol. 2013 Sep;40(9):1634. Alten, Rieke [added].

PMID:
23418379
16.

2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R; American College of Rheumatology.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447-61. doi: 10.1002/acr.21773. No abstract available.

17.

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R; American College of Rheumatology.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46. doi: 10.1002/acr.21772. No abstract available.

18.

Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.

Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL.

J Rheumatol. 2012 Jul;39(7):1450-7. doi: 10.3899/jrheum.111375. Epub 2012 Jun 1.

19.

2011 recommendations for the diagnosis and management of gout and hyperuricemia.

Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, Doghramji PP, Guadagnoli GA, Hamburger F, Harford R, Lieberman JA 3rd, Mandel DR, Mandelbrot DA, McClain BP, Mizuno E, Morton AH, Mount DB, Pope RS, Rosenthal KG, Setoodeh K, Skosey JL, Edwards NL.

Phys Sportsmed. 2011 Nov;39(4):98-123. doi: 10.3810/psm.2011.11.1946. Review.

PMID:
22293773
20.

2011 Recommendations for the diagnosis and management of gout and hyperuricemia.

Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, Doghramji PP, Guadagnoli GA, Hamburger F, Harford R, Lieberman JA 3rd, Mandel DR, Mandelbrot DA, McClain BP, Mizuno E, Morton AH, Mount DB, Pope RS, Rosenthal KG, Setoodeh K, Skosey JL, Edwards NL; European League Against Rheumatism.

Postgrad Med. 2011 Nov;123(6 Suppl 1):3-36. doi: 10.3810/pgm.2011.11.2511.

PMID:
22156509
21.

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA.

JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169.

PMID:
21846852
22.

Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials.

Taylor WJ, Singh JA, Saag KG, Dalbeth N, MacDonald PA, Edwards NL, Simon LS, Stamp LK, Neogi T, Gaffo AL, Khanna PP, Becker MA, Schumacher HR Jr.

J Rheumatol. 2011 Jul;38(7):1467-70. doi: 10.3899/jrheum.110274.

PMID:
21724718
23.

Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?

Stamp LK, Khanna PP, Dalbeth N, Boers M, Maksymowych WP, Schumacher HR Jr, Becker MA, MacDonald PA, Edwards NL, Singh JA, Simon LS, McQueen FM, Neogi T, Gaffo AL, Strand V, Taylor WJ.

J Rheumatol. 2011 Jul;38(7):1462-6. doi: 10.3899/jrheum.110273.

24.

Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities.

Dalbeth N, McQueen FM, Singh JA, MacDonald PA, Edwards NL, Schumacher HR Jr, Simon LS, Stamp LK, Neogi T, Gaffo AL, Khanna PP, Becker MA, Taylor WJ.

J Rheumatol. 2011 Jul;38(7):1458-61. doi: 10.3899/jrheum.110272.

25.

Patient-reported outcomes in chronic gout: a report from OMERACT 10.

Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, McQueen FM, Neogi T, Gaffo AL, Becker MA, MacDonald PA, Dabbous O, Strand V, Dalbeth ND, Aletaha D, Edwards NL, Schumacher HR Jr.

J Rheumatol. 2011 Jul;38(7):1452-7. doi: 10.3899/jrheum.110271.

26.

Quality of care in patients with gout: why is management suboptimal and what can be done about it?

Edwards NL.

Curr Rheumatol Rep. 2011 Apr;13(2):154-9. doi: 10.1007/s11926-010-0154-6.

PMID:
21161617
27.

Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy.

Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA.

J Med Econ. 2011;14(1):10-5. doi: 10.3111/13696998.2010.540874. Epub 2010 Dec 7.

PMID:
21138339
28.

Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers.

Stamp LK, Zhu X, Dalbeth N, Jordan S, Edwards NL, Taylor W.

Semin Arthritis Rheum. 2011 Jun;40(6):483-500. doi: 10.1016/j.semarthrit.2010.09.003. Epub 2010 Nov 5. Review.

PMID:
21056459
29.

Managing gout in the primary care setting: what you and your patients need to know.

Doghramji PP, Edwards NL, McTigue J.

Am J Med. 2010 Aug;123(8):S2. doi: 10.1016/j.amjmed.2010.06.005.

PMID:
20670699
30.

Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion.

Mandell BF, Edwards NL, Sundy JS, Simkin PA, Pile JC.

Cleve Clin J Med. 2010 Jun;77 Suppl 2:S2-25. doi: 10.3949/ccjm.77.s2.01. No abstract available.

PMID:
20516241
31.

Febuxostat: a new treatment for hyperuricaemia in gout.

Edwards NL.

Rheumatology (Oxford). 2009 May;48 Suppl 2:ii15-ii19. doi: 10.1093/rheumatology/kep088. Review.

PMID:
19447778
32.

Progress in measurement instruments for acute and chronic gout studies.

Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, Schlesinger N, Evans R, Edwards NL, Sivera F, Diaz-Torne C, MacDonald PA, McQueen FM, Schumacher HR.

J Rheumatol. 2009 Oct;36(10):2346-55. doi: 10.3899/jrheum.090371.

PMID:
19820224
33.

Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?

Gaffo AL, Edwards NL, Saag KG.

Arthritis Res Ther. 2009;11(4):240. doi: 10.1186/ar2761. Epub 2009 Aug 19. Review.

34.

The role of hyperuricemia in vascular disorders.

Edwards NL.

Curr Opin Rheumatol. 2009 Mar;21(2):132-7. doi: 10.1097/BOR.0b013e3283257b96. Review. Erratum in: Curr Opin Rheumatol. 2010 Jan;22(1):107.

PMID:
19339923
35.

Toward a valid definition of gout flare: results of consensus exercises using Delphi methodology and cognitive mapping.

Taylor WJ, Shewchuk R, Saag KG, Schumacher HR Jr, Singh JA, Grainger R, Edwards NL, Bardin T, Waltrip RW, Simon LS, Burgos-Vargas R.

Arthritis Rheum. 2009 Apr 15;61(4):535-43. doi: 10.1002/art.24166.

36.

In defense of research into the crystal induced arthropathies.

Dalbeth N, Perez-Ruiz F, Edwards NL, Schlesinger N.

J Rheumatol. 2008 Nov;35(11):2278-9; author reply 2279. doi: 10.3899/jrheum.080599. No abstract available.

PMID:
19004057
37.

Pain management in gout.

Kirby BS, McTigue JC, Edwards NL.

Curr Pain Headache Rep. 2008 Dec;12(6):418-22. Review.

PMID:
18973734
38.

The role of hyperuricemia and gout in kidney and cardiovascular disease.

Edwards NL.

Cleve Clin J Med. 2008 Jul;75 Suppl 5:S13-6. Review.

PMID:
18822470
39.

Treatment-failure gout: a moving target.

Edwards NL.

Arthritis Rheum. 2008 Sep;58(9):2587-90. doi: 10.1002/art.23803. No abstract available.

40.

Febuxostat : a viewpoint by N. Lawrence Edwards.

Edwards NL.

Drugs. 2008;68(13):1875-6. No abstract available.

PMID:
18729540
41.

Outcome evaluations in gout.

Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N, Khanna D, Furst DE, Becker MA, Dalbeth N, Edwards NL.

J Rheumatol. 2007 Jun;34(6):1381-5.

PMID:
17552064
42.

Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency.

Edwards NL.

Am J Med. 2006 Nov;119(11 Suppl 1):S29-31. No abstract available.

PMID:
17059911
43.

Case 7: differential diagnosis of advanced gout.

Edwards NL.

Am J Med. 2006 Nov;119(11 Suppl 1):S23-4. No abstract available.

PMID:
17059909
44.

Case 6: maintenance therapy for simple intermittent gout.

Edwards NL.

Am J Med. 2006 Nov;119(11 Suppl 1):S20-2. No abstract available.

PMID:
17059908
45.

Magnetic resonance imaging in the quantitative assessment of gouty tophi.

Schumacher HR Jr, Becker MA, Edwards NL, Palmer WE, MacDonald PA, Palo W, Joseph-Ridge N.

Int J Clin Pract. 2006 Apr;60(4):408-14. Erratum in: Int J Clin Pract. 2006 May;60(5):630.

PMID:
16620352
46.

Treatment of osteoarthritis.

Barnes EV, Edwards NL.

South Med J. 2005 Feb;98(2):205-9. Erratum in: South Med J. 2005 May;98(5):574.

PMID:
15759951
47.

Magnetic resonance imaging of tophaceous gout in the hands and wrists.

Popp JD, Bidgood WD Jr, Edwards NL.

Semin Arthritis Rheum. 1996 Feb;25(4):282-9.

PMID:
8834016
48.

Clinical pathogenesis and diagnosis of osteoarthritis.

Fiske DN, Edwards NL.

Contemp Intern Med. 1995 Jun;7(6):13-6, 21-5, 30-1. Review.

PMID:
10150438
49.

Axial skeletal changes in paralysed patients may mimic ankylosing spondylitis.

Fiske DN, Bush CH, Edwards NL.

Br J Rheumatol. 1995 Feb;34(2):174-7.

PMID:
7704467
50.

New insights into gouty arthritis.

Popp JD, Edwards NL.

Contemp Intern Med. 1995 Jan;7(1):55-64. Review. No abstract available.

PMID:
10150333

Supplemental Content

Loading ...
Support Center